Thioredoxin signaling as a target for cancer therapy
Section snippets
The thioredoxin family of redox proteins
The thioredoxin redox system comprises thioredoxin reductase (TR), a homodimeric selenium containing flavoprotein, which transfers reducing equivalents from NADPH to the small (12 kDa) redox protein thioredoxin (Trx). Trx has a conserved Cys-Gly-Pro-Cys redox catalytic site that in turn, reduces client proteins or binds to proteins to modify their activity. For full details of the Trx system the reader is referred to excellent reviews [1, 2]. This overview will be concerned with only the most
Thioredoxin as a validated cancer drug target
Most attention has been focused on Trx-1 and TR1 as targets for cancer therapy, although the increasing evidence of the importance of the UPR to protein synthesis and survival of cancer cells [6] suggests that the ER Trx family members may be therapeutic targets for cancer in their own right. Trx-1 has multiple functions in the cell (Figure 1) that include providing reducing equivalents for DNA synthesis through ribonucleotide reductase (RR), and for reactive oxygen radical scavenging through
Thioredoxin reductase as a cancer drug target
There are three mammalian TRs, TR1, TR2 and a third form TR3 expressed primarily in the testis that can also reduce glutathione disulfide. All three TRs are selenoproteins with a glutathione reductase-like base structure and a C-terminal 16 amino acid elongation containing the Gly-Cys-Sec-Gly active site. Structural studies have shown that the TR1 C-terminal catalytic site is readily accessible [25] and because of this TR is a promiscuous enzyme with a number of different substrates and
Antitumor thioredoxin inhibitors
AW464, a benzathiole-substituted quinol with antitumor activity has been reported to inhibit Trx-1 and TR, and to inhibit the proliferation of tumor cell lines and endothelial cells [31]. Paradoxically, AW464 and a related compound decrease HIF-1α transcriptional activity, DNA binding and the expression of VEGF, but at the same time increase HIF-1α protein levels [32]. A Trx-1 antisense phosphorothiote oligodeoxynucleotide GTI-2601 has been reported to exhibit in vivo antitumor activity in
Inhibitors of thioredoxin reductase
A number of electrophilic compounds inhibit TR, including organogold compounds such as auranofin that is used to treat rheumatoid arthritis, arsenicals [41], antitumor agents including the nitrosoureas, platinum agents such as cis-diamminedichloroplatin [42], antitumor quinols [43] and the newer anticancer agents myricetin, quercetin [44] and curcumin [45]. However, the agents can also inhibit other oxidoreductases and NF-κB, and the contribution of TR inhibition to their biological activity is
Conclusion
Trx family members play critical roles in the regulation of cellular redox homeostasis. Cancer cells exist in a stressed environment and rely on the Trxs for protection against stress-disregulated redox signaling. The most extensively studied member of the family is Trx-1 whose levels are increased in many human tumors most likely in direct response to microenvironment stress. Trx-1 contributes to many of the hallmarks of cancer including increased proliferation, resistance to cell death and
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Conflict disclosure
Dr Powis is a founder, stockholder and consultant to ProlX Pharmaceuticals. Dr Kirkpatrick is a founder, stockholder and employee of ProlX Pharmaceuticals. One of the thioredoxin inhibitors discussed, PX-12, is a ProlX drug.
Acknowledgement
The work is supported by NIH Grant CA77204.
References (50)
- et al.
The thioredoxin system in cancer
Semin Cancer Biol
(2006) - et al.
Similarities and differences in the thioredoxin superfamily
Prog Biophys Mol Biol
(2006) - et al.
ERdj5, an endoplasmic reticulum (ER)-resident protein containing DnaJ and thioredoxin domains, is expressed in secretory cells or following ER stress
J Biol Chem
(2003) - et al.
Identification of a novel thioredoxin-related transmembrane protein
J Biol Chem
(2001) - et al.
Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma
FEBS Lett
(2006) - et al.
The nonclassic secretion of thioredoxin is not sensitive to redox state
Am J Physiol—Cell Physiol
(2003) - et al.
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival
Human Pathol
(2000) - et al.
Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin
Cancer Res
(1996) - et al.
Three dimensional structure of mammalian thioredoxin reductase: implications for mechanistic and evolutions of a selenocysteine-dependent enzyme
Proc Natl Acad Sci USA
(2001) - et al.
Decreased IGF1-R and EGFR expression by the thioredoxin inhibitor PX-12 is mediated by SP-1 inhibition
Proc Am Assoc Cancer Res
(2005)